The Latest Cardiac and Vascular News
To provide a full spectrum of innovative solutions, the partnership aims to empower better heart care and build efficiency across the care pathway journey of the patient Unlocking the potential of interventional cardiology will be a step forward in delivering precision health BENGALURU, India, Aug. 16, 2022 /PRNewswire/ — GE Healthcare, a leading global […]
Company to add novel technology cleared for use in peripheral vasculature to interventional oncology and embolization portfolio MARLBOROUGH, Mass., Aug. 15, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM™) technology used for embolization of blood […]
MARLBOROUGH, Mass., July 27, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported basis, 9.6 percent on an operational1 basis and 6.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]
MARLBOROUGH, Mass., June 15, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to purchase its majority stake (approximately 64 percent) of M.I.Tech Co., Ltd, (“M.I.Tech”) a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and […]
MARLBOROUGH, Mass., April 28, 2022 – Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EMBOLD™ Fibered Detachable Coil, which is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature. The first procedure using the device was performed this week […]
MARLBOROUGH, Mass., April 27, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]
MARLBOROUGH, Mass., Feb. 28, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Presented during a late-breaking trial session at the Cardiovascular Research Technologies (CRT) 2022 meeting, the SURPASS analysis included data from more […]
MARLBOROUGH, Mass., Feb. 15, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. “The close of this acquisition allows Boston Scientific to integrate the […]
Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD MARLBOROUGH, Mass., Dec. 2, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM […]
MARLBOROUGH, Mass., Oct. 27, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and 10.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net […]
